🟢 87/100

This product is generally safe

  • Niacin: 500mg is 14.3× the Tolerable Upper Intake Level (35mg)
  • 67% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 500mg is 14.3× the Tolerable Upper Intake Level (35mg)

Label Data

1 Tablet(s) Serving Size
120 Servings
Other Combinations Product Type
67% Evidence Coverage

Supplement Facts — Evidence Check

500 mg (3125% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 14.3× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 500mg UL 35mg
Calcium
40 mg (3% DV)
30 mg (2% DV)
📊 Market median: 99.0mg (503 products) 📚 12 studies (Tier A: 0, B: 3)
RDA 700mg This product: 30mg UL 4000mg

Other Ingredients

Microcrystalline Cellulose Hydroxypropylmethylcellulose Magnesium Stearate Coating Silica

Label Claims — Verification

Nutrient
All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Vegetarian Adult (18 - 50 Years) Women (not pregnant or lactating) Gluten Free

Product Information

📋 Directions for Use

Directions: Take one tablet with a meal one to two times daily or as directed by your healthcare practitioner.

⚠️ Warnings & Precautions

Caution: Niacin use may be associated with itching and/or flushing.

Warning: Do not use if pregnant or breastfeeding or if you have a history of gout or liver dysfunction. Larger than recommended doses of niacin have been associated with liver dysfunction. If taking cholesterol lowering medications, please discuss with your clinician prior to use.

🧪 Formulation Notes

Niatain features a high quality form of nicotinic acid in an extended release formula designed to reduce the flushing normally associated with niacin intake. It has been formulated with a non-wax coating for effective dissolution.

For decades, niacin has been extensively researched and endorsed as support for healthy lipid metabolism.

This product is non-GMO, gluten-free, and vegetarian.

This product is non-GMO, gluten-free, and vegetarian.

Support for healthy lipid metabolism

Additional Information

Storage: Keep tightly closed in a cool, dry place.

GF Certified Gluten-free

New formula

Practitioner exclusive

Product Details

UPC / SKU 7 55571 92407 0
DSLD Entry Date 2020-03-24
Product Type Other Combinations
Form Tablet or Pill
Brand Metagenics
DSLD ID 216308
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →